PGR and breast carcinoma: We found that 1,721 (75.6%) of the 2,276 patients with tumors with intermediate Ki-67 expression (that is, comprising patients meeting the old and new thresholds) had substantial PgR positivity (≥20%) and had outcomes similar to those of patients with luminal A–like breast cancer, thus confirming the correct classification of this subgroup of patients.